Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Opdivo Dosing Simplified; Yosprala, Cuvitru Approved; Telotristat Review Lengthened

Related Content

FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake

Jan 14 2013

KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence

Sep 16 2016

Keeping Track: FDA On A Complete Response Spree?

Apr 04 2016

Spectrum's Apaziquone Pooled Analysis Can't Make Up For Negative Studies

Sep 14 2016

More Bad News For Pozen: Another Delay To Market For Yosprala

Dec 17 2014

Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors

Jun 30 2016

Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road

Jun 20 2016

Approval Might Be The Least Of Aralez's Challenges With <em>Yosprala</em>

Jul 21 2016

Related Companies

Aralez Pharmaceuticals Inc.

Bristol Myers Squibb Company

Takeda Pharmaceutical Co. Ltd.

GSK plc

Zevra Therapeutics, Inc.

Spectrum Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

Tesaro, Inc.

Bristol Myers Squibb Company

Baxalta Incorporated

Matinas BioPharma Holdings, Inc.

MGB Biopharma Limited

Additional Topics

United States Approvals Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window